On August 24, 2020, Connecticut Biopharmaceuticals (hereinafter referred to as Connected Biopharmaceuticals) announced the completion of a $115 million Series C financing. This round of financing was led by RACapitalManagement, with participation from LillyAsiaVentures (Lilly Asia Fund), BoxerCapital and HBMHealthcareInvestments, and the existing investor QimingVenturePartners (Qiming Ventures) continued to follow. With this round of financing in place, Dr. Derek DiRocco, Executive Director of RACapitalManagement, will join the Connecticut Board of Directors as a new Director.

The funds from this round of financing will be mainly used to advance the Phase II clinical trial of the innovative drug CBP-201 in the treatment of moderate to severe atopic dermatitis (AD), and to accelerate the clinical trial of another innovative drug CBP-307 in the treatment of ulcerative colitis (UC). Phase II clinical trials, and clinical development for the treatment of moderate to severe Crohn’s disease (CD); it will also be used to expand the clinical development of new indications for CBP-201, and the future Phase III of two new drugs, CBP-201 and CBP-307 Production of clinical trial samples. In addition, part of the funds from this round of financing will also be used to advance the research of other new products into the clinical stage, including advancing the first-in-human (Phase I) clinical study of CBP-174, the world’s first small molecule drug for the treatment of pruritus.

In the first half of 2020, Connecticut Bio has achieved several important milestones. On January 9, Connecticut announced that the new drug CBP-201 under investigation had achieved positive results in the Phase Ib clinical study of moderate to severe AD patients, and on July 20 announced the initiation of the global AD clinical Phase IIb trial of the product; The global intellectual property protection of CBP-307, a new drug candidate with broad market potential in immune diseases, has been strengthened. In addition, ConnectBio plans to advance CBP-174, a small molecule drug for the treatment of pruritus, into Phase I clinical trials in the fourth quarter of this year.

About Conrad Bio

Connected Bio is a U.S. and China-based biopharmaceutical company focused on the development of new drugs for the treatment of autoimmune diseases and inflammation, co-founded by Dr. Wei Zheng and Dr. Wubin Pan.

Before founding Conrad Bio, Zheng Wei served as the director of immunology in Arena Pharmaceuticals, USA, leading the development of new drugs in the field of inflammation and autoimmunity and successfully completed three autoimmune R&D projects. Deputy Director of the Department and Scientist of Ligand Pharmaceuticals. Pan Wubin has nearly 20 years of experience in biomedical research and development, and has published more than 20 scientific papers and 3 invention patents. He has served as a senior, senior scientist and project leader in foreign biotechnology companies.

So far, Connected Bio has successfully obtained US$200 million in investment from top domestic and foreign institutions such as RACapital, Eli Lilly Asia Fund, HBM Healthcare Investments, Qiming Ventures, Shangxun, etc. It is actively promoting the industrialization process of new drug products, and plans to submit an IPO in the future Listing application.

Connected Bio has established a high-throughput drug screening platform based on the immune regulation function of T cells. Compared with traditional methods, this platform can quickly and efficiently identify and screen disease therapeutic molecules against related targets. Currently, Connected Bio is developing differentiated immunomodulators, including orally active small molecule modulators and monoclonal antibodies, to address unmet clinical needs in autoimmune diseases and allergic inflammation.

Connecticut Bio has global rights to all products in its new drug pipeline. One of two major programs in the clinical pipeline, CBP-307, is currently in Phase II clinical studies in ulcerative colitis (UC) and Crohn’s disease (CD); CBP-201 is currently in clinical trials for moderate Phase Ib clinical study in patients with severe atopic dermatitis.

In addition to CBP-201 and CBP-307, ConnectBio is simultaneously advancing three preclinical programs, including two small molecule drug candidates (CBP-174 and CBP-312) and an antibody targeting IL-33 ( CBP-233), for the treatment of a variety of severe inflammatory diseases, and currently, CBP-174 is about to undergo an application for clinical trials.

About CBP-201

CBP-201 is an anti-IL-4Rα monoclonal antibody. In Th2 cell-mediated inflammatory diseases, IL-4 and IL-13 are two key pro-inflammatory factors, and their biological functions overlap significantly. 4Rα. CBP-201 is a new antibody drug independently developed by Conrad through its unique immune regulation technology platform. It is currently in the clinical development stage for the treatment of moderate to severe atopic dermatitis and other Th2-type inflammatory diseases that do not meet clinical treatment needs.

The results of the phase Ib clinical study of CBP-201 in adult patients with moderate to severe atopic dermatitis showed that the drug has a good safety profile, and after 4 weeks of treatment, its efficacy is better than the current efficacy data of standard treatment for atopic dermatitis . The study found that 42.9% and 50.0% of patients treated with CBP-201 300mg and 150mg, respectively, achieved “clear/substantially clear” skin lesions at 4 weeks of treatment, compared with the efficacy of existing standard treatment, This is particularly striking. In addition, the study demonstrated improvement in affected skin lesions in only 1 week after administration, accompanied by a rapid decrease in itch intensity and frequency.

About CBP-307

CBP-307 is a novel second-generation agonist of sphingosine-1-phosphate receptor 1 (S1P1), a G protein-coupled receptor (GPCR) that plays a central role in regulating T cell motility. CBP-307 was discovered using Connected’s proprietary T cell screening platform, and is the most clinically active S1P1 agonist reported so far, with excellent physicochemical properties. In two completed Phase I randomized, double-blind, placebo-controlled studies, CBP-307 demonstrated potent T cell modulating activity and safety. CBP-307 is currently undergoing two Phase II studies to evaluate its efficacy and safety in patients with moderate-to-severe ulcerative colitis and moderate-to-severe Crohn’s disease.

Leave a Reply

Your email address will not be published.